EEG Signals in Psychiatry: Biomarkers for Depression Management - Quantitative EEG Analysis Methods and Clinical Applications - page 314

[118] Bruder, G. E., et al., “Dichotic Listening Tests of Functional Brain Asymmetry Predict
Response to Fluoxetine in Depressed Women and Men,” Neuropsychopharmacology ,
Vol. 29, September 2004, pp. 1752-1761.
[119] Stewart, J. W., et al., “Do Tricyclic Responders Have Different Brain Laterality?” J.
Abnorm. Psychol. , Vol. 108, November 1999, pp. 707-710.
[120] Bruder, G. E., et al., “Electroencephalographic and Perceptual Asymmetry Differences
Between Responders and Nonresponders to an SSRI Antidepressant,” Biol. Psychiatry ,
Vol. 49, March 1, 2001, pp. 416-425.
[121] Bruder, G. E., et al., “Electroencephalographic Alpha Measures Predict Therapeutic
Response to a Selective Serotonin Reuptake Inhibitor Antidepressant: Pre- and Post-Treat-
ment Findings,” Biol. Psychiatry , Vol. 63, June 15, 2008, pp. 1171-1177.
[122] Otto, M. W., et al., “Perceptual Asymmetry, Plasma Cortisol, and Response to Treatment in
Depressed Outpatients,” Biol. Psychiatry , Vol. 30, October 1, 1991, pp. 703-710.
[123] Keller, M. B., et al., “Optimizing Outcomes in Depression: Focus on Antidepressant Com-
pliance,” Int. Clin. Psychopharmacol. , Vol. 17, November 2002, pp. 265-271.
[124] Melfi, C. A., et al., “The Effects of Adherence to Antidepressant Treatment Guidelines on
Relapse and Recurrence of Depression,” Arch. Gen. Psychiatry , Vol. 55, December 1998,
pp. 1128-1132.
[125] Hunter, A. M., et al., “Neurophysiologic Correlates of Side Effects in Normal Subjects Ran-
domized to Venlafaxine or Placebo,” Neuropsychopharmacology , Vol. 30, April 2005,
pp. 792-799.
[126] Beasley, C. M., Jr., et al., “Fluoxetine and Adult Suicidality Revisited: An Updated
Meta-Analysis Using Expanded Data Sources from Placebo-Controlled Trials,” J. Clin.
Psychopharmacol. , Vol. 27, December 2007, pp. 682-6.
[127] Simon, G. E., et al., “Suicide Risk During Antidepressant Treatment,” Am. J. Psychiatry ,
Vol. 163, January 2006, pp. 41-47.
[128] U.S. Food and Drug Administration, Antidepressant Use in Children, Adolescents, and
Adults, www.fds.gov/CDER/Drug?antidepressants/default.htm, 2004.
[129] Perlis, R. H., et al., “Treatment-Associated Suicidal Ideation and Adverse Effects in an
Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes,” Psychother.
Psychosom. , Vol. 76, 2007, pp. 40-46.
[130] Hrobjartsson, A., and P. C. Gotzsche, “Is the Placebo Powerless? An Analysis of Clinical
Trials Comparing Placebo with No Treatment,” N. Engl. J. Med. , Vol. 344, May 24, 2001,
pp. 1594-1602.
[131] Thase, M. E., and P. T. Ninan, “New Goals in the Treatment of Depression: Moving
Toward Recovery,” Psychopharmacol. Bull. , Vol. 36, Suppl. 2, Summer 2002, pp. 24-35.
[132] Leuchter, A. F., et al., “Changes in Brain Function of Depressed Subjects During Treatment
with Placebo,” Am. J. Psychiatry , Vol. 159, January 2002, pp. 122-129.
[133] Mayberg, H. S., et al., “The Functional Neuroanatomy of the Placebo Effect,” Am. J. Psy-
chiatry , Vol. 159, May 2002, pp. 728-737.
[134] Leuchter, A. F., et al., “Pretreatment Neurophysiological and Clinical Characteristics of
Placebo Responders in Treatment Trials for Major Depression,” Psychopharmacology
(Berl.) , Vol. 177, December 2004, pp. 15-22.
[135] Hunter, A. M., et al., “Changes in Brain Function (Quantitative EEG Cordance) During Pla-
cebo Lead-In and Treatment Outcomes in Clinical Trials for Major Depression,” Am. J.
Psychiatry , Vol. 163, August 2006, pp. 1426-1432.
[136] Laupacis, A., D. L. Sackett, and R. S. Roberts, “An Assessment of Clinically Useful Mea-
sures of the Consequences of Treatment,” N. Engl. J. Med. , Vol. 318, June 30, 1988,
pp. 1728-1733.
[137] Altman, D. G., and J. M. Bland, “Diagnostic Tests 2: Predictive Values,” BMJ , Vol. 309,
July 9, 1994, p. 102.